Genzyme Warns Of Further Shortages Of Cerezyme, Fabrazyme
This article was originally published in The Pink Sheet Daily
Executive Summary
Fabrazyme may be unavailable in some regions from July through September, the company warned.
You may also be interested in...
Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth
Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.
Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth
Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.
Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval
Ahead of the big pharma's earnings call July 29, Sanofi-Aventis is under renewed pressure with Momenta and partner Sandoz promising a swift launch of their newly approved generic version of Lovenox.